Luteotropic and luteolytic factors regulate mRNA and protein expression of progesterone receptor isoforms A and B in the bovine endometrium

2016 ◽  
Vol 28 (7) ◽  
pp. 907 ◽  
Author(s):  
Robert Rekawiecki ◽  
Magdalena Karolina Kowalik ◽  
Jan Kotwica
Keyword(s):  
Progesterone Receptor ◽  
Protein Expression ◽  
Mrna Expression ◽  
Expression Analysis ◽  
Oestrous Cycle ◽  
Nitric Oxide Donor ◽  
Mrna Sequence ◽  
Progesterone Receptor Isoforms ◽  
Protein Levels ◽  
Receptor Isoforms

The aim of the present study was to examine the effects of luteotropic and luteolytic factors on the mRNA and protein levels of progesterone receptor isoforms A (PGRA) and B (PGRB) in the bovine endometrium. Endometrial slices from Days 6–10 and 17–20 of the oestrous cycle were treated with LH (100 ng mL–1), oestradiol (E2; 1 × 10–8 M), prostaglandin (PG) E2 (1 × 10–6 M) and PGF2α (1 × 10–6 M) and the nitric oxide donor NONOate (1 × 10–4 M); these treatments lasted for 6 h for mRNA expression analysis and 24 h for protein expression analysis. On Days 6–10 of the oestrous cycle PGRAB (PGRAB; the entire PGRA mRNA sequence is common to the PGRB mRNA sequence) mRNA expression in endometrial slices was enhanced by E2 treatment (P < 0.001), whereas PGRB mRNA expression was increased by LH (P < 0.001), E2 (P < 0.05) and NONOate (P < 0.05) treatment. On Days 17–20, PGRAB mRNA expression increased after E2 (P < 0.001) and PGE2 (P < 0.05) treatment; PGRB mRNA expression was increased by PGE2 (P < 0.05) and PGF2α (P < 0.01) treatment, but decreased by LH (P < 0.05). On Days 6–10 protein levels of PGRA were stimulated by E2 (P < 0.01), whereas PGRB protein levels were increased by LH (P < 0.05) and E2 (P < 0.05). On Days 17–20 of the oestrous cycle, PGRA protein levels were enhanced by E2 (P < 0.05) and PGF2α (P < 0.05), whereas PGRB protein levels were stimulated by PGE2 (P < 0.05) and PGF2α (P < 0.001). These data suggest that luteotropic and luteolytic factors affect PGRA and PGRB mRNA and protein levels, and this may regulate the effects of progesterone on endometrial cells.

Cloning and expression of progesterone receptor isoforms A and B in bovine corpus luteum

2015 ◽  
Vol 27 (7) ◽  
pp. 1029 ◽  
Author(s):  
Robert Rekawiecki ◽  
Magdalena Karolina Kowalik ◽  
Jan Kotwica
Keyword(s):  
Mrna Level ◽  
First Trimester ◽  
Oestrous Cycle ◽  
Cloning And Expression ◽  
Corpora Lutea ◽  
Mrna Levels ◽  
Variable Expression ◽  
Progesterone Receptor Isoforms ◽  
Protein Levels ◽  
Receptor Isoforms

Progesterone (P4) affects a cell through its nuclear receptor (PGR), which has two main isoforms: A (PGRA) and B (PGRB). A partial section of previously unknown PGRB cDNA from cattle was cloned. Next, mRNA and protein levels for these two isoforms in corpora lutea (CL) collected during different stages of the oestrous cycle and pregnancy were determined. The PGRB mRNA level was highest on Days 2–5 of the oestrous cycle, decreased over the next few days (P < 0.01) and increased again slightly on Days 17–20 (P < 0.05). During pregnancy, PGRB mRNA was at its lowest level during Weeks 3–5 (P < 0.01) and highest during Weeks 6–12 (P < 0.01). The profile of PGRA mRNA levels was similar to that of PGRB throughout the oestrous cycle. The PGRA protein level was highest on Days 2–10 of the oestrous cycle, decreased continuously to its lowest concentration on Days 17–20 (P < 0.01) and during Weeks 3–5 of pregnancy (P > 0.05) and increased during Weeks 6–12 (P < 0.05). PGRB protein concentration followed a similar pattern but at a markedly lower level. Both PGRA and PGRB isoforms are involved in the regulation of P4 action, especially in the newly formed CL and developed CL in the first trimester of pregnancy. These data suggest that the variable expression of these isoforms during the oestrous cycle may depend on the influence of P4.

scholarly journals Characterization of Nuclear Progesterone Receptor Isoforms in the Term Equine Placenta

2021 ◽  
Vol 8 ◽  
Author(s):  
Ahmed M. Nagy ◽  
Swanand R. Sathe ◽  
Attia H. Atta ◽  
Abdel Mohsen M. Hammam ◽  
Walter H. Hsu
Keyword(s):  
Progesterone Receptor ◽  
Placental Tissue ◽  
Progesterone Receptor Isoforms ◽  
Protein Levels ◽  
Receptor Isoforms ◽  
Protein Expressions ◽  
Integral Role ◽  
Nuclear Progesterone Receptor

In equine parturition, the role of progestins along with the nuclear progesterone receptor (nPR) signaling pathway in the placenta is not completely clarified. The progestins play an integral role in maintaining myometrial quiescence during the late stage of pregnancy via acting on nPR isoforms (PRA and PRB; PRB is more active than PRA). The current study aimed to determine the PRA and PRB expressions in the term equine placenta at the gene and protein levels. Six term equine placentas were used in this study. Reverse transcription polymerase chain reaction (RT-PCR) was used to quantify the mRNA expression for PRA and PRB. The protein expression was detected using the Western Blot technique. The results revealed that the mRNA and protein expressions for PRA were significantly higher (P &lt; 0.0001) in the term equine placental tissue compared to the mRNA and protein expressions of PRB. These results demonstrated that nPRs are detectable in the term placenta of mares and PRA is the dominant isoform expressed. The present findings raised the possibility that the PRA plays an important role in the parturition process and expulsion of the placenta in mares.

scholarly journals Ratio of mRNA expression of progesterone receptor isoforms AB is to b in human oviduct mucosal cells during the ovulatory cycle

2005 ◽  
Vol 22 (11-12) ◽  
pp. 429-435 ◽  
Author(s):  
Christine Briton-Jones ◽  
Ingrid Hung Lok ◽  
Che Kwok Cheung ◽  
Alice Lai See Po ◽  
Tony TY Chiu ◽  
...  
Keyword(s):  
Progesterone Receptor ◽  
Mrna Expression ◽  
Ovulatory Cycle ◽  
Progesterone Receptor Isoforms ◽  
Receptor Isoforms ◽  
Mucosal Cells ◽  
Human Oviduct

Progesterone receptor isoforms differentially regulate the expression of tryptophan and tyrosine hydroxylase and glutamic acid decarboxylase in the rat hypothalamus

2011 ◽  
Vol 59 (5) ◽  
pp. 671-676 ◽  
Author(s):  
Oscar González-Flores ◽  
Porfirio Gómora-Arrati ◽  
Marcos García-Juárez ◽  
Alfredo Miranda-Martínez ◽  
Alejandra Armengual-Villegas ◽  
...  
Keyword(s):  
Tyrosine Hydroxylase ◽  
Progesterone Receptor ◽  
Glutamic Acid ◽  
Glutamic Acid Decarboxylase ◽  
Acid Decarboxylase ◽  
Rat Hypothalamus ◽  
Progesterone Receptor Isoforms ◽  
Receptor Isoforms

scholarly journals Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate Receptors

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Grzegorz Sulkowski ◽  
Beata Dąbrowska-Bouta ◽  
Lidia Strużyńska
Keyword(s):  
Experimental Autoimmune Encephalomyelitis ◽  
Protein Expression ◽  
Mrna Expression ◽  
Glutamate Receptors ◽  
Neurological Deficits ◽  
Autoimmune Encephalomyelitis ◽  
Protein Levels ◽  
Group I ◽  
Group I Mglurs ◽  
Experimental Autoimmune

The aim of our investigation was to characterize the role of group I mGluRs and NMDA receptors in pathomechanisms of experimental autoimmune encephalomyelitis (EAE), the rodent model of MS. We tested the effects of LY 367385 (S-2-methyl-4-carboxyphenylglycine, a competitive antagonist of mGluR1), MPEP (2-methyl-6-(phenylethynyl)-pyridine, an antagonist of mGluR5), and the uncompetitive NMDA receptor antagonists amantadine and memantine on modulation of neurological deficits observed in rats with EAE. The neurological symptoms of EAE started at 10-11 days post-injection (d.p.i.) and peaked after 12-13 d.p.i. The protein levels of mGluRs and NMDA did not increase in early phases of EAE (4 d.p.i.), but starting from 8 d.p.i. to 25 d.p.i., we observed a significant elevation of mGluR1 and mGluR5 protein expression by about 20% and NMDA protein expression by about 10% over the control at 25 d.p.i. The changes in protein levels were accompanied by changes in mRNA expression of group I mGluRs and NMDARs. During the late disease phase (20–25 d.p.i.), the mRNA expression levels reached 300% of control values. In contrast, treatment with individual receptor antagonists resulted in a reduction of mRNA levels relative to untreated animals.

Sign in / Sign up

Export Citation Format

Share Document